DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pazopanib
Pazopanib
Horizon Scanning Status Report June 2019
Lenvatinib in Advanced, Radioactive Iodine– Refractory, Differentiated Thyroid Carcinoma Kay T
Votrient, INN-Pazopanib
BC Cancer Benefit Drug List September 2021
Preliminary Findings on the Use of Targeted Therapy with Pazopanib and Other Agents in Combination with Sodium Phenylbutyrate in the Treatment of Glioblastoma Multiforme
Pazopanib
Imatinib, Sunitinib and Pazopanib DPOG; Westerdijk, Kim; Desar, I
Hypopigmentation of the Skin and Hair Associated with Targetedclinical Therapies and BIOMEDICAL INVESTIGATION
Clinical Pharmacology and Biopharmaceutics Review(S)
An Impressive Response to Pazopanib in a Patient with Metastatic Endometrial Carcinoma
Interstitial Lung Disease Induced by Pazopanib Treatment for Metastatic Renal Cell Carcinoma at the Time of COVID-19 Pandemic
Unitedhealthcare Cancer Therapy Pathways Program Regimens
Neoadjuvant Combination of Pazopanib Or Axitinib And
PROTOCOL UMCC 2016.013 Pilot Study of Pazopanib with Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma Principal Investigator
Targeted Therapy for HER2 Positive Breast Cancer Jason a Incorvati1, Shilpan Shah1, Ying Mu2 and Janice Lu1,2*
Axitinib for Treating Advanced Renal Cell Carcinoma After Failure of Prior Systemic Treatment
Pharmacology Review(S)
VOTRIENT (Pazopanib) Tablets (5.6) Initial U.S
Top View
Bladder Cancer
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
VOTRIENT (Pazopanib) Tablets Gastrointestinal Perforation Or Fistula
Effect of Tyrosine Kinase Inhibitors on Renal Handling of Creatinine By
Avelumab 20Mg/Ml Concentrate for Solution for Infusion (Bavencio®) Merck Kgaa/Pfizer
Open Full Page
Maximizing Clinical Outcomes with Axitinib Therapy in Advanced Renal Cell Carcinoma Through Proactive Side-Effect Management
Synergistic Proapoptotic Effects of the Two Tyrosine Kinase Inhibitors Pazopanib and Lapatinib on Multiple Carcinoma Cell Lines
X FACT SHEET
A16-63 Lenvatinib (Renal Cell Carcinoma) – Benefit Assessment According to §35A Social Code Book V1
Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent in Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification
A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients With
SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
Adult Antiemetic Management of Chemotherapy-Induced Nausea
The Small-Molecule VEGF Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma
Lenvatinib (Lenvima™), Pazopanib (Votrient®), Sorafenib (Nexavar®) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO166
Pazopanib in Renal Cell Carcinoma
Neoadjuvant Pazopanib and Molecular Analysis of Tissue Response in Renal Cell Carcinoma